로타바이러스 백신의 최신 지견

다국어 초록 (Multilingual Abstract)

Rotavirus is the most common cause of severe gastroenteritis in infants and young chilren throughout the
world. And the rates of rotavirus gastroenteritis among children in industrialized and less developed countries
are similar.
Therefore rotavirus vaccine would have universal application as part of immunization program. And
cost-effectiveness analyses have shown that rotavirus immunization program would be cost-effective from the
perspective of society and the health care system.
On the base of a number of effective clinical trial in infants worldwide, 2 recently developed vaccines,
pentavalent human-bovine reassortant rotavirus vaccine(RotaTeq )and human rotavirus Ⓡ vaccine(RotarixTM)
were licensed in the United States and Korea, recently.
These 2 vaccines are high efficacy, excellent tolerability, and no increased risk of intussusception in each
clinical trials of more than 60,000 infants.
Vaccination against rotavirus will substantially reduce rotavirus gastroenteritis associated morbidity and
mortality.